ASH Clinical News ACN_4.9_Digital_Issue | Page 20

Literature Scan Presence of Minimal Residual Disease Predicts Relapse and Survival in AML For patients with acute myeloid leuke- mia (AML), the detection of molecular minimal residual disease (MRD) in patients achieving morphologic complete remission (CR) was associated with a higher risk of relapse and a lower risk of relapse-free survival, according to a study published in The New England Journal of Medicine. Recurrent mutations associated with clonal hematopoiesis of indetermi- nate potential (CHIP) during a four-year follow-up period, however, did not pro- vide this prognostic value. “In this study, genetic sequencing and multiparameter flow cytometry each had independent and additive prognostic value with respect to rates of relapse and survival in patients with AML,” the authors, led by Mojk Jongen- Lavrencic, MD, PhD, from Erasmus University Medical Center in Rotterdam, Netherlands, wrote. “The detection of residual leukemia with both methods is associated with an excessively high prob- ability of relapse (approximately 75%).” Conversely, “the absence of [MRD] is correlated with a relatively low probabil- ity of relapse (approximately 25%).” The trial enrolled 482 patients with previously untreated AML or myelodys- plastic syndromes involving refractory anemia with excess blasts; all partici- pants were in CR or CR with incomplete hematologic recovery (CRi) and were considered to be at high or very-high risk of relapse (defined as a >4.5 score on the Revised International Prognostic Scoring System). Patients underwent targeted next- generation sequencing at diagnosis and during CR to detect mutations in 54 genes associated with hematologic malignancies. MRD also was detected using multiparameter flow cytometry. Nearly 90 percent of patients (n=430) had at least one mutation at diagnosis, and the average number of mutations was 2.9 per patient. The most common of these were mutations in NPM1, DNMT3A, FLT3, and NRAS. During CR, 51.4 percent of these patients had persistent mutations and “the rate at which mutations persisted was highly variable across genes,”